AUTHORS
Jie Wang, MD, Nainong Li, MD2, Xiaofan Li Sr, MD, PhD3
AFFILIATIONS
1 Fujian Institute of Hematology,Fujian Provincial Key Laboratory on Hematology,Fujian Medical University Union Hospital, Fuzhou, fujian, China, The Second Affiliated Hospital of Shandong First Medical University, Tai’an City, Shandong Province 271000, China
2 Fujian Institute of Hematology,Fujian Provincial Key Laboratory on Hematology,Fujian Medical University Union Hospital, Fuzhou, fujian, China
3 Fujian Institute of Hematology,Fujian Provincial Key Laboratory on Hematology,Fujian Medical University Union Hospital, Fuzhou, fujian, China
ABSTRACT
Matched Sibling Donor Transplantation With or Without Sequential Umbilical Cord Blood Infusion: Clinical Outcomes and Significance of Final Graft Dominance
Background: Relapse remains a major cause of treatment failure after matched sibling donor (MSD) hematopoietic stem cell transplantation (HSCT). MSD transplantation with sequential UCB infusion (MSD-UCB transplantation) may enhance graft-versus-leukemia (GVL) activity, but its impact on clinical outcomes and significance of final graft dominance remain uncertain. We compared outcomes of MSD transplantation with versus without UCB infusion and explored outcomes according to final graft dominance patterns.
Methods: We retrospectively analyzed 279 patients with hematologic malignancies undergoing allogeneic HSCT between 2014 and 2025. Of these, 123 received MSD transplantation alone, and 156 received MSD-UCB transplantation. Within the MSD-UCB cohort, outcomes were further evaluated according to final chimerism pattern (MSD-dominant vs UCB-dominant). Outcomes were assessed through 2 years after transplantation and included overall survival (OS), disease-free survival (DFS), graft-versus-host disease-free/relapse-free survival (GRFS), relapse mortality (RM), cumulative incidence of relapse (CIR), nonrelapse mortality (NRM), and neutrophil and platelet engraftment. Separate inverse probability of treatment weighting (IPTW) analyses were conducted for the treatment-strategy and graft-dominance comparisons. IPTW achieved covariate balance in the treatment-strategy comparison, because some residual imbalance remained after weighting in the graft-dominance comparison, the corresponding outcome models further adjusted for these differences. Cox and Fine–Gray models were used for survival and competing-risk outcomes, respectively. Because graft dominance was determined after transplantation, this analysis was considered exploratory.
Results: For MSD transplantation alone versus MSD-UCB transplantation, the unadjusted 2-year OS was 61.8% versus 74.4%, DFS 56.8% versus 70.5%, GRFS 38.5% versus 57.4%, RM 21.9% versus 9.9%, CIR 26.8% versus 13.7%, and NRM 16.3% versus 15.8%. In IPTW analyses, MSD-UCB transplantation was associated with reduced risk of death (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.36–0.96; P=0.034), DFS (HR, 0.60; 95% CI, 0.38–0.96; P=0.031), and GRFS (HR, 0.62; 95% CI, 0.43–0.89; P=0.010). MSD-UCB transplantation was also associated with lower RM (subdistribution HR [sHR], 0.36; 95% CI, 0.17–0.74; P=0.006) and CIR (sHR, 0.44; 95% CI, 0.23–0.83; P=0.012), without evidence of higher NRM (sHR, 0.90; 95% CI, 0.46–1.76; P=0.765). Neutrophil engraftment did not differ significantly (sHR, 0.81; 95% CI, 0.62–1.06; P=0.118), whereas platelet engraftment was slower with sequential UCB infusion (sHR, 0.73; 95% CI, 0.54–0.99; P=0.045).
Among MSD-UCB recipients, 114 were MSD-dominant and 42 were UCB-dominant at final chimerism assessment. Unadjusted 2-year OS was 73.2% with MSD-dominant chimerism and 77.8% with UCB-dominant chimerism; corresponding estimates were 68.0% and 77.8% for DFS, 56.0% and 61.9% for GRFS, 12.4% and 2.4% for RM, 17.6% and 2.4% for CIR, and 14.3% and 19.8% for NRM. After IPTW and residual adjustment, UCB-dominant chimerism was not associated with OS (HR, 1.33; 95% CI, 0.52–3.40; P=0.546), DFS (HR, 1.01; 95% CI, 0.39–2.62; P=0.990), or GRFS (HR, 0.99; 95% CI, 0.40–2.42; P=0.981). UCB-dominant chimerism was associated with lower RM (sHR, 0.11; 95% CI, 0.01–0.87; P=0.037) and CIR (sHR, 0.06; 95% CI, 0.01–0.49; P=0.009), but higher NRM (sHR, 2.60; 95% CI, 1.08–6.25; P=0.033) and slower neutrophil (sHR, 0.46; 95% CI, 0.31–0.70; P<0.001) and platelet engraftment (sHR, 0.54; 95% CI, 0.36–0.80; P=0.002).
Conclusions: Sequential UCB infusion may represent a dual-graft transplantation strategy for MSD transplantation, associated with favorable survival and disease control without evidence of excess NRM. The contrasting outcomes of UCB-dominant chimerism suggest that clinical benefit may arise from early graft interactions rather than durable UCB engraftment alone. Further prospective and mechanistic studies are warranted.
DISCLOSURES
Jie Wang, MD: No relevant conflicts of interest to declare.